RUNX1 is altered in 14.8% of acute myeloid leukemia patients with RUNX1 Loss present in 0.1% of all acute myeloid leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 34 clinical trials for acute myeloid leukemia, of which 28 are open and 6 are closed. Of the trials that contain RUNX1 Loss and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (6 open), 5 are phase 1/phase 2 (5 open), 17 are phase 2 (15 open), 1 is phase 2/phase 3 (0 open), and 2 are phase 3 (1 open) [5].

RUNX1 is altered in 11.64% of myelodysplastic syndromes patients [4].

RUNX1 Loss is an inclusion criterion in 24 clinical trials for myelodysplastic syndromes, of which 20 are open and 4 are closed. Of the trials that contain RUNX1 Loss and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (3 open), 6 are phase 1/phase 2 (6 open), 12 are phase 2 (10 open), and 1 is phase 2/phase 3 (0 open) [5].

RUNX1 is altered in 19.79% of chronic myelomonocytic leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 10 clinical trials for chronic myelomonocytic leukemia, of which 8 are open and 2 are closed. Of the trials that contain RUNX1 Loss and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (5 open) [5].

RUNX1 is altered in 14.29% of acute lymphoblastic leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 0 are closed. Of the trials that contain RUNX1 Loss and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 6 are phase 2 (6 open) [5].

RUNX1 Loss is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain RUNX1 Loss and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

RUNX1 is altered in 7.23% of secondary acute myeloid leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 4 clinical trials for secondary acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain RUNX1 Loss and secondary acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].

RUNX1 is altered in 0.85% of non-hodgkin lymphoma patients with RUNX1 Loss present in 0.07% of all non-hodgkin lymphoma patients [4].

RUNX1 Loss is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (2 open) [5].

RUNX1 is altered in 5.98% of chronic myeloid leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 3 clinical trials for chronic myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 Loss and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 3 clinical trials for hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 Loss and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

RUNX1 Loss is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 Loss and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

RUNX1 is altered in 14.29% of T-cell acute lymphoblastic leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 Loss and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

RUNX1 is altered in 7.23% of therapy-related acute myeloid leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain RUNX1 Loss and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

RUNX1 is altered in 0.77% of B-cell non-hodgkin lymphoma patients with RUNX1 Loss present in 0.09% of all B-cell non-hodgkin lymphoma patients [4].

RUNX1 Loss is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 2 clinical trials for acute bilineal leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 Loss and acute bilineal leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 2 clinical trials for acute biphenotypic leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 Loss and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 Loss and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 Loss and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

RUNX1 is altered in 5.63% of secondary myelodysplastic syndrome patients [4].

RUNX1 Loss is an inclusion criterion in 2 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 Loss and secondary myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (1 open) [5].

RUNX1 is altered in 22.0% of acute myeloid leukemia with myelodysplasia-related changes patients with RUNX1 Loss present in 0.94% of all acute myeloid leukemia with myelodysplasia-related changes patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [5].

RUNX1 is altered in 1.32% of diffuse large B-cell lymphoma patients with RUNX1 Loss present in 0.2% of all diffuse large B-cell lymphoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

RUNX1 is altered in 0.8% of pancreatic carcinoma patients with RUNX1 Loss present in 0.16% of all pancreatic carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 1.45% of lymphoma patients with RUNX1 Loss present in 0.11% of all lymphoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 14.81% of acute leukemia patients with RUNX1 Loss present in 0.09% of all acute leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 3.23% of melanoma patients with RUNX1 Loss present in 0.09% of all melanoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 4.26% of breast carcinoma patients with RUNX1 Loss present in 0.08% of all breast carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 14.36% of leukemia patients with RUNX1 Loss present in 0.08% of all leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 1.98% of malignant solid tumor patients with RUNX1 Loss present in 0.08% of all malignant solid tumor patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 2.04% of colorectal carcinoma patients with RUNX1 Loss present in 0.07% of all colorectal carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 1.67% of head and neck carcinoma patients with RUNX1 Loss present in 0.06% of all head and neck carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 1.96% of glioblastoma patients with RUNX1 Loss present in 0.05% of all glioblastoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 0.73% of sarcoma patients with RUNX1 Loss present in 0.03% of all sarcoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 1.27% of non-small cell lung carcinoma patients with RUNX1 Loss present in 0.01% of all non-small cell lung carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 1.07% of anaplastic astrocytoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 3.91% of bladder carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 is altered in 20.0% of chronic myelomonocytic leukemia-0 patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RUNX1 is altered in 8.11% of chronic myelomonocytic leukemia-1 patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RUNX1 is altered in 35.71% of chronic myelomonocytic leukemia-2 patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

RUNX1 is altered in 0.78% of histiocytic and dendritic cell neoplasm patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RUNX1 is altered in 1.42% of indolent non-hodgkin lymphoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

RUNX1 is altered in 0.94% of mature T-cell and NK-cell neoplasm patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RUNX1 is altered in 18.75% of mixed phenotype acute leukemia patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 16.0% of myelodysplastic syndrome with excess blasts-2 patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (0 open) [5].

RUNX1 is altered in 15.38% of myelodysplastic/myeloproliferative neoplasm patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 15.15% of myelodysplastic/myeloproliferative neoplasm, unclassifiable patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

RUNX1 is altered in 3.01% of myelofibrosis patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 3.09% of myeloproliferative neoplasm patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 0.82% of ovarian carcinoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

RUNX1 is altered in 0.57% of polycythemia vera patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 3.54% of primary myelofibrosis patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for refractory anemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and refractory anemia as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 14.88% of refractory anemia with excess blasts patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 1.17% of T-cell non-hodgkin lymphoma patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RUNX1 is altered in 5.63% of therapy-related myelodysplastic syndrome patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

RUNX1 is altered in 5.56% of waldenstrom macroglobulinemia patients [4].

RUNX1 Loss is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 Loss and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [5].